Projectoproep Grants 2016 : laureaten

Fundamenteel onderzoek: 31 laureaten - 12 114 838 €

  • Aerts Stein, Katholieke Universiteit Leuven
    Deciphering the regulatory code underlying a common epigenomic survival switch in cancer
  • Berx Geert, Universiteit Gent
    Emt a novel imortant determinant of melanoma heterogenecity and progression
  • Beyaert Rudi, Universiteit Gent
    Role of MALT1 proteolytic activity in prostate cancer
  • Blanpain Cedric, Université Libre de Bruxelles
    Mechanisms regulating metastasis-initiating cells in squamous cell carcinoma
  • Bollen Mathieu, Katholieke Universiteit Leuven  
    Phosphatase-directed targeting of the DNA-repair capacity in cancer
  • Bommer Guido, Université catholique de Louvain
    Role of side-activities of glycolytic enzymes in cancer development and future therapy
  • Breckpot Karine, Vrije Universiteit Brussel
    Nanobody-targeted radionuclide therapy and immune therapy: a perfect match in the era of combination therapy
  • Carmeliet Geert, Katholieke Universiteit Leuven
    Breast tumor cell metabolism as driver of bone micrometastases
  • Carmeliet Peter, Katholieke Universiteit Leuven    
    Improving immunotherapy via tumor vessel normalization by blocking endothelial cell glycolysis
  • Chariot Alain, Université de Liège
    Cross talk between EGFR and Plexin signaling in solid tumors
  • Close Pierre, Université de Liège
    Implication of tRNA modification in cancer
  • De Keersmaecker Kim, KU Leuven Kulak    
    Oncogenic mechanisms of ribosomal protein L5 in glioblastoma    
  • Declercq Wim, Universiteit Gent
    RIPK4, a novel target in cancer therapy
  • Detours Vincent, Université Libre de Bruxelles
    RNA Editing in Breast Cancer and ADAR Inhibition
  • Elewaut Dirk, Universiteit Gent    
    Role of endoplasmic reticulum (ER) stress induced immunogenic lipids in cancer immunotherapy
  • Feron Olivier, Université catholique de Louvain    
    Fatty acid metabolism under tumor acidosis: from the molecular determinants to innovative therapies
  • Fuks François, Université Libre de Bruxelles
    An innovative approach to study the role of RNA epigenetics in cancer
    Support given jointly by the Funds José Plé-Albert Declercq, Nicolas Dehu, Louis Bourdon and DV. These funds are managed by the King Boudouin Foundation.
  • Gallez Bernard, Université catholique de Louvain
    PDK inhibitors to block tumor cell proliferation: Rationale for combined treatment strategies counteracting compensatory mechanisms that sustain tumor growth
  • Halder Georg, Katholieke Universiteit Leuven
    Regenerative Cancer Therapy: a novel approach to fight against cancer
  • Jacquemin Patrick, Université catholique de Louvain
    Mechanism of resistance to oncogenic mutations of Kras in pancreatic acinar cells
  • Janssens Veerle, Katholieke Universiteit Leuven    
    The biological role and therapeutic biomarker potential of PPP2R4, a PP2A activating protein with tumor suppressive properties, in KRAS wild-type and mutant lung cancers: a pre-clinical proof-of-concept study in human and mouse NSCLC models
  • Legius Eric, Katholieke Universiteit Leuven
    Importance of SPRED1 in melanoma
  • Lucas Sophie, Université catholique de Louvain
    Targeting GARP/TGF-β1 complexes on human regulatory T cells: a novel approach for cancer immunotherapy
  • Swinnen Johan, Katholieke Universiteit Leuven
    Fatty acid metabolism as a key mediator of therapy resistance in BRAF-mutant malignant melanoma
  • Taghon Tom, Universiteit Gent
    Characterisation of the oncogenic mechanisms induced by GATA3 mutations in cancer
  • Tejpar Sabine, Katholieke Universiteit Leuven
    ZIC2 acts as a chromatin modifier to determine cell fate specification in stem cells and cancer
  • Van Ginderachter Jo, Vrije Universiteit Brussel
    Defining the role of Kupffer cells during liver metastasis formation
  • Vandekerckhove Bart, Universiteit Gent
    The role of a novel innate CD8 positive T cell population in the defense against cancer
  • Vandenabeele Peter, Universiteit Gent    
    Cell death modality regulation during immunotherapy (CREDIT): molecular mechanisms and experimental therapy
  • Voets Thomas, Katholieke Universiteit Leuven    
    TRPM3 as target for chemotherapy-induced peripheral neuropathic pain
  • Wen-Hui Lien, Université catholique de Louvain    
    Deciphering the tumorigenic potential of non-canonical Wnt signaling pathways and their crosstalk with Wnt/β-catenin signaling during skin tumorigenesis

Fundamenteel onderzoek Asbest: 4 laureaten - 992 876 €

  • Feron Olivier, Université catholique de Louvain
    Photodynamic therapy of mesothelioma: a new photosensitizer acting as a ER stressor
  • van Meerbeeck Jan, Universitaire Ziekenhuis Antwerpen
    Identification of potentially actionable genetic alterations in solid and liquid biopsies of patients with malignant pleural mesothelioma.
  • Willems Luc,Université de Liège
    Fine tuned ubiquitin-dependent regulation of DNA damage tolerance in mesothelioma
  • Zimmermann Pascale, Katholieke Universiteit Leuven
    Merlin-syntenin interaction in MPM exosome production and Hippo signaling           

Translationeel en klinisch onderzoek: 37 laureaten - 8 135 909 €

  • Baron Frédéric, Université de Liège
    Chronic GVHD : role of regulatory T cells (Treg) and of JAK
  • Beguin Yves, Université de Liège
    Cerebral GVHD
  • Berneman Zwi, Universitair Ziekenhuis Antwerpen
    Multicenter randomized phase II trial of Wilms' tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in patients with acute myeloid leukemia
  • Ceelen Wim, Universiteit Gent
    Role of the peritoneal microenvironment in the pathogenesis and spread of colorectal carcinomatosis
  • Claes Kathleen, Matthijs Gert & De Grève Jacques : Universitair Ziekenhuis Gent, KU Leuven & Vrije Universiteit Brussel
    HBOC (Hereditary Breast and Ovarian Cancer), a paradigm shift for counseling and treatment of patients with defects in homologous recombination – an explorative study
  • Cools Jan, Katholieke Universiteit Leuven
    JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
  • de Freitas Nascimento Luana, Belgian Nuclear Research Centre
    In vivo dose assessment using a 2D imaging system
  • De Keersmaecker Kim, KU Leuven Kulak
    Somatic ribosome mutations as targets for cancer therapy
  • De Moerloose Barbara, Universiteit Gent
    Evaluation of long non-coding RNAs as novel therapeutic targets in Juvenile Myelomonocytic Leukemia (JMML)
  • Debyser Zeger Van Vlierberghe Pieter : KU Leuven & Universiteit Gent
    Development of a new therapeutic strategy for MLL-rearranged leukemia
  • Delvenne Philippe, Université de Liège
    Combining PD-1/PD-L1 blockade and HMGB1 inhibitors for treating oropharyngeal and breast cancers unresponsive to standard therapy
  • Deprez Sabine, Katholieke Universiteit Leuven
    What causes cognitive decline in chemotherapy treated cancer survivors? An integrative study using multi-model brain imaging, cognitive testing, measurement of stress & inflammatory biomarkers.
  • D'Huyvetter Matthias, Vrije Universiteit Brussel
    Nanobody-Based Targeted Radionuclide Therapy of Multiple Myeloma: a feasibility study
  • Docquier Pierre-Louis, Université catholique de Louvain
    The use of PSI (patient specific instrument) to improve the safe margins in the surgery of bone sarcoma’s resection. Check of the margin by MRI
  • Dolmans Marie-Madeleine, Université catholique de Louvain
    Human Ovary Preservation Expertise (HOPE): fertility preservation options for all patients
  • Franchimont Denis, Université Libre de Bruxelles
    GENomic profilinG of ColitIS-associated Colorectal CANcer  (GENGISCAN)
  • Goossens Steven, Universiteit Gent
    Oncogenic ZEB2 activation drives sensitivity towards LSD1 inhibition
  • Havelange Violaine, Cliniques Universitaires Saint-Luc, UCL
    MicroRNAs and resistance to chemotherapy
  • Hernot Sophie, Vrije Universiteit Brussel
    Hybrid near-infrared fluorescence and nuclear imaging in ovarian cancer with uPAR-specific nanobodies for intra-operative navigation
  • Ignatiadis Michail, Institut Jules Bordet
    Plasma circulating tumor DNA (ctDNA) in primary breast cancer: a SUCCESS A translational study proposal
  • Lambrechts Diether, Katholieke Universiteit Leuven
    A Nanopore Long-read Sequencing-based Approach to more Accurately Detect Predictive Biomarkers for Cancer Immunotherapy
  • Laureys Geneviève, Universiteit Gent
    Familial childhood cancer cases as a treasure-trove for detection of predisposing mutations
  • Mestdagh Pieter, Universiteit Gent
    Targeting the melanoma-specific lncRNA SAMMSON as a novel therapeutic strategy for ocular melanoma
  • Neyns Bart, Universitaire Ziekenhuis Brussel
    Phase I clinical trial program on autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with immune-checkpoint blockade and cytokine therapy
  • Nuyts Sandra, Katholieke Universiteit Leuven
    Targeted inhibition of DNA repair as a strategy to tackle radiation resistance in head and neck cancers
  • Ost Piet, Universiteit Gent
    "PEACE VI: a randomized phase III trial for the Treatment of OligoREcurrent Nodal prostate cancer (TOREN)
  • Préat Veronique, Université catholique de Louvain
    Local Delivery of nanomedicines-loaded hydrogel for the treatment of glioblastoma
  • Sotiriou Christos, Institut Jules Bordet
    Identification of genomic alterations associated with prognosis and the efficacy of endocrine therapy (tamoxifen vs aromatase inhibitor) according to breast cancer histological subtypes (ductal vs lobular) in the SOFT, TEXT and BIG 1-98 trials
  • Tejpar Sabine, Katholieke Universiteit Leuven
    When is a polyp born to be bad? Omics exploration of those features that are involved in malignant transformation
  • Tombal Bertrand, Cliniques Universitaires Saint-Luc, UCL
    A phase II multicentric trial study evaluating the feasibility, efficiency and tolerance of targeted high frequency focus ultrasound ablation (focal therapy) of MRI detected intermediate risk localized prostate cancer.
  • Van Damme An, Belgian Society for Pediatric Hematology and Oncology
    BSPHO (Belgian Society for Pediatric Hematology and Oncology) participation in international academic clinical trials in Pediatric Oncology
  • Van Damme Nancy *, Foundation Belgian Cancer Registry
    Molecular tumor characteristics: indispensable for population-based registries?
    136 000 € in addition of the Grants 2016 envelope (decision of the Board of direction of 07/12/2016)
  • Van den Eynde Marc, Cliniques Universitaires Saint-Luc, UCL
    Translational work on a neoadjuvant combination of chemoradiotherapy and anti-PD-L1 antibody for patients with locally advanced rectal cancer  
  • Van Tendeloo Viggo, Universiteit Antwerpen
    Wilms’ tumor 1-specific T cell receptor (TCR) RNA-modified T cells for adoptive immunotherapy of cancer: moving towards clinical application
  • Vandenberghe Peter, Universitaire Ziekenhuizen Leuven
    Circulating cell-free DNA: a novel gateway to the genome of Hodgkin/Reed-Sternberg cells in Hodgkin Lymphoma?
  • Veldeman Liv & Remouchamps Vincent :Universiteit Gent & UCL Namur, site Sainte-Elisabeth    
    Prone crawl radiotherapy for whole-breast and lymph node irradiation
  • Wyns Christine, Université catholique de Louvain
    Fertility restauration after cancer in young boys: creating an artificial testis

Translationeel en klinisch onderzoek Asbest: 2 laureaten - 365 000 €

  • Berneman Zwi & Germonpré Paul : Universiteit Antwerpen & AZ Maria Middelares
    Improving frontline treatment for malignant pleural mesothelioma with concomitant platinum/pemetrexed-based chemotherapy and Wilms’ tumor protein 1 (WT1)-targeted dendritic cell immunotherapy
  • Willems Luc, Université de Liège
    Polycomb repressor complex mediated polarisation of tumoricidal macrophages in malignant mesothelioma
Laatst aangepast op: 17/11/2017


“Toen mijn vrouw onlangs te horen kreeg dat ze borstkanker heeft, kwam de ziekte opeens wel heel dichtbij… Nochtans steunen we de Stichting al jaren, omdat we het belangrijk vinden een steentje bij te dragen en omdat de Stichting op een ethisch verantwoorde manier fondsen werft. Ik was dan ook meteen gewonnen voor het concept ‘Vriend van de Stichting’. Als je als Stichting weet waarop je kan rekenen, kun je beter plannen en nog meer vooruitgang helpen boeken. Het gaat maar om een klein bedrag, maar alle beetjes helpen.”Lees verder